XML 55 R21.htm IDEA: XBRL DOCUMENT
v3.24.2

SEGMENT INFORMATION | 6 Months Ended
--- | ---
Jun. 30, 2024
Segment Reporting [Abstract] |
SEGMENT INFORMATION | SEGMENT INFORMATION Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business. The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs. Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail- order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics. In addition, our CenterWell intersegment revenues include revenues earned by certain owned providers derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service. We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $4.8 billion and $5.0 billion for the three months ended June 30, 2024 and 2023, respectively. For the six months ended June 30, 2024 and 2023, these amounts were $8.5 billion and $9.0 billion respectively. In addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $32 million and $34 million for the three months ended June 30, 2024 and 2023, respectively, and $64 million and $67 million for the six months ended June 30, 2024 and 2023, respectively. Other than those described previously, the accounting policies of each segment are the same. For additional information regarding our accounting policies refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below. Our segment results were as follows for the three and six months ended June 30, 2024 and 2023:
| Insurance |  | CenterWell |  | Eliminations/ Corporate |  | Consolidated
Three months ended June 30, 2024 | (in millions)
External revenues |  |  |  |  |  |
Premiums: |  |  |  |  |  |  |
Individual Medicare Advantage | $ | 22,215 |  |  | $ | — |  |  | $ | — |  |  | $ | 22,215 |
Group Medicare Advantage | 1,938 |  |  | — |  |  | — |  |  | 1,938 |
Medicare stand-alone PDP | 867 |  |  | — |  |  | — |  |  | 867 |
Total Medicare | 25,020 |  |  | — |  |  | — |  |  | 25,020 |
Commercial fully-insured | 152 |  |  | — |  |  | — |  |  | 152 |
Specialty benefits | 240 |  |  | — |  |  | — |  |  | 240 |
Medicare Supplement | 206 |  |  | — |  |  | — |  |  | 206 |
State-based contracts and other | 2,524 |  |  | — |  |  | — |  |  | 2,524 |
Total premiums | 28,142 |  |  | — |  |  | — |  |  | 28,142 |
Services revenue: |  |  |  |  |  |  |
Home solutions | — |  |  | 335 |  |  | — |  |  | 335 |
Primary care | — |  |  | 322 |  |  | — |  |  | 322 |
Commercial ASO | 8 |  |  | — |  |  | — |  |  | 8 |
Military services and other | 206 |  |  | — |  |  | — |  |  | 206 |
Pharmacy solutions | — |  |  | 229 |  |  | — |  |  | 229 |
Total services revenue | 214 |  |  | 886 |  |  | — |  |  | 1,100 |
Total external revenues | 28,356 |  |  | 886 |  |  | — |  |  | 29,242 |
Intersegment revenues |  |  |  |  |  |  |
Services | 1 |  |  | 1,416 |  |  | (1,417) |  |  | — |
Products | — |  |  | 2,645 |  |  | (2,645) |  |  | — |
Total intersegment revenues | 1 |  |  | 4,061 |  |  | (4,062) |  |  | — |
Investment income | 168 |  |  | — |  |  | 130 |  |  | 298 |
Total revenues | 28,525 |  |  | 4,947 |  |  | (3,932) |  |  | 29,540 |
Operating expenses: |  |  |  |  |  |  |
Benefits | 25,182 |  |  | — |  |  | (143) |  |  | 25,039 |
Operating costs | 2,395 |  |  | 4,553 |  |  | (3,800) |  |  | 3,148 |
Depreciation and amortization | 185 |  |  | 56 |  |  | (29) |  |  | 212 |
Total operating expenses | 27,762 |  |  | 4,609 |  |  | (3,972) |  |  | 28,399 |
Income from operations | 763 |  |  | 338 |  |  | 40 |  |  | 1,141 |
Interest expense | — |  |  | 1 |  |  | 167 |  |  | 168 |
Other expense, net | — |  |  | — |  |  | 55 |  |  | 55 |
Income (loss) before income taxes and equity in net earnings | 763 |  |  | 337 |  |  | (182) |  |  | 918 |
Equity in net income (losses) | 1 |  |  | (18) |  |  | — |  |  | (17) |
Segment earnings (loss) | $ | 764 |  |  | $ | 319 |  |  | $ | (182) |  |  | $ | 901 |
Net loss attributable to noncontrolling interests | 1 |  |  | — |  |  | — |  |  | 1 |
Segment earnings (loss) attributable to Humana | $ | 765 |  |  | $ | 319 |  |  | $ | (182) |  |  | $ | 902 |
| Insurance |  | CenterWell |  | Eliminations/ Corporate |  | Consolidated
Three months ended June 30, 2023 | (in millions)
External revenues |  |  |  |  |  |
Premiums: |  |  |  |  |  |  |
Individual Medicare Advantage | $ | 19,749 |  |  | $ | — |  |  | $ | — |  |  | $ | 19,749 |
Group Medicare Advantage | 1,732 |  |  | — |  |  | — |  |  | 1,732 |
Medicare stand-alone PDP | 568 |  |  | — |  |  | — |  |  | 568 |
Total Medicare | 22,049 |  |  | — |  |  | — |  |  | 22,049 |
Commercial fully-insured | 950 |  |  | — |  |  | — |  |  | 950 |
Specialty benefits | 252 |  |  | — |  |  | — |  |  | 252 |
Medicare Supplement | 182 |  |  | — |  |  | — |  |  | 182 |
State-based contracts and other | 2,062 |  |  | — |  |  | — |  |  | 2,062 |
Total premiums | 25,495 |  |  | — |  |  | — |  |  | 25,495 |
Services revenue: |  |  |  |  |  |  |
Home solutions | — |  |  | 341 |  |  | — |  |  | 341 |
Primary care | — |  |  | 190 |  |  | — |  |  | 190 |
Commercial ASO | 64 |  |  | — |  |  | — |  |  | 64 |
Military services and other | 167 |  |  | — |  |  | — |  |  | 167 |
Pharmacy solutions | — |  |  | 216 |  |  | — |  |  | 216 |
Total services revenue | 231 |  |  | 747 |  |  | — |  |  | 978 |
Total external revenues | 25,726 |  |  | 747 |  |  | — |  |  | 26,473 |
Intersegment revenues |  |  |  |  |  |  |
Services | 15 |  |  | 1,144 |  |  | (1,159) |  |  | — |
Products | — |  |  | 2,639 |  |  | (2,639) |  |  | — |
Total intersegment revenues | 15 |  |  | 3,783 |  |  | (3,798) |  |  | — |
Investment income | 134 |  |  | — |  |  | 140 |  |  | 274 |
Total revenues | 25,875 |  |  | 4,530 |  |  | (3,658) |  |  | 26,747 |
Operating expenses: |  |  |  |  |  |  |
Benefits | 22,127 |  |  | — |  |  | (118) |  |  | 22,009 |
Operating costs | 2,545 |  |  | 4,193 |  |  | (3,627) |  |  | 3,111 |
Depreciation and amortization | 172 |  |  | 50 |  |  | (31) |  |  | 191 |
Total operating expenses | 24,844 |  |  | 4,243 |  |  | (3,776) |  |  | 25,311 |
Income from operations | 1,031 |  |  | 287 |  |  | 118 |  |  | 1,436 |
Interest expense | — |  |  | 1 |  |  | 119 |  |  | 120 |
Other expense, net | — |  |  | — |  |  | 54 |  |  | 54 |
Income (loss) before income taxes and equity in net earnings | 1,031 |  |  | 286 |  |  | (55) |  |  | 1,262 |
Equity in net earnings (losses) | 1 |  |  | (11) |  |  | — |  |  | (10) |
Segment earnings (loss) | $ | 1,032 |  |  | $ | 275 |  |  | $ | (55) |  |  | $ | 1,252 |
Net loss attributable to noncontrolling interests | 3 |  |  | — |  |  | — |  |  | 3 |
Segment earnings (loss) attributable to Humana | $ | 1,035 |  |  | $ | 275 |  |  | $ | (55) |  |  | $ | 1,255 |
| Insurance |  | CenterWell |  |  |  |  |  | Eliminations/ Corporate |  | Consolidated
Six months ended June 30, 2024 | (in millions)
External revenues |  |  |  |  |  |  |  |  |  |
Premiums: |  |  |  |  |  |  |  |  |  |  |
Individual Medicare Advantage | $ | 44,663 |  |  | $ | — |  |  |  |  |  |  | $ | — |  |  | $ | 44,663 |
Group Medicare Advantage | 3,927 |  |  | — |  |  |  |  |  |  | — |  |  | 3,927 |
Medicare stand-alone PDP | 1,688 |  |  | — |  |  |  |  |  |  | — |  |  | 1,688 |
Total Medicare | 50,278 |  |  | — |  |  |  |  |  |  | — |  |  | 50,278 |
Commercial fully-insured | 408 |  |  | — |  |  |  |  |  |  | — |  |  | 408 |
Specialty benefits | 479 |  |  | — |  |  |  |  |  |  | — |  |  | 479 |
Medicare Supplement | 403 |  |  | — |  |  |  |  |  |  | — |  |  | 403 |
State-based contracts and other | 4,835 |  |  | — |  |  |  |  |  |  | — |  |  | 4,835 |
Total premiums | 56,403 |  |  | — |  |  |  |  |  |  | — |  |  | 56,403 |
Services revenue: |  |  |  |  |  |  |  |  |  |  |
Home solutions | — |  |  | 670 |  |  |  |  |  |  | — |  |  | 670 |
Primary care | — |  |  | 563 |  |  |  |  |  |  | — |  |  | 563 |
Commercial ASO | 32 |  |  | — |  |  |  |  |  |  | — |  |  | 32 |
Military services and other | 457 |  |  | — |  |  |  |  |  |  | — |  |  | 457 |
Pharmacy solutions | — |  |  | 440 |  |  |  |  |  |  | — |  |  | 440 |
Total services revenue | 489 |  |  | 1,673 |  |  |  |  |  |  | — |  |  | 2,162 |
Total external revenues | 56,892 |  |  | 1,673 |  |  |  |  |  |  | — |  |  | 58,565 |
Intersegment revenues |  |  |  |  |  |  |  |  |  |  |
Services | 2 |  |  | 2,830 |  |  |  |  |  |  | (2,832) |  |  | — |
Products | — |  |  | 5,262 |  |  |  |  |  |  | (5,262) |  |  | — |
Total intersegment revenues | 2 |  |  | 8,092 |  |  |  |  |  |  | (8,094) |  |  | — |
Investment income | 330 |  |  | — |  |  |  |  |  |  | 256 |  |  | 586 |
Total revenues | 57,224 |  |  | 9,765 |  |  |  |  |  |  | (7,838) |  |  | 59,151 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |
Benefits | 50,433 |  |  | — |  |  |  |  |  |  | (270) |  |  | 50,163 |
Operating costs | 4,759 |  |  | 9,036 |  |  |  |  |  |  | (7,605) |  |  | 6,190 |
Depreciation and amortization | 371 |  |  | 109 |  |  |  |  |  |  | (59) |  |  | 421 |
Total operating expenses | 55,563 |  |  | 9,145 |  |  |  |  |  |  | (7,934) |  |  | 56,774 |
Income from operations | 1,661 |  |  | 620 |  |  |  |  |  |  | 96 |  |  | 2,377 |
Interest expense | — |  |  | 2 |  |  |  |  |  |  | 325 |  |  | 327 |
Other expense, net | — |  |  | — |  |  |  |  |  |  | 118 |  |  | 118 |
Income (loss) before income taxes and equity in net losses | 1,661 |  |  | 618 |  |  |  |  |  |  | (347) |  |  | 1,932 |
Equity in net losses | (1) |  |  | (40) |  |  |  |  |  |  | — |  |  | (41) |
Segment earnings (loss) | $ | 1,660 |  |  | $ | 578 |  |  |  |  |  |  | $ | (347) |  |  | $ | 1,891 |
Net loss attributable to noncontrolling interests | 3 |  |  | — |  |  |  |  |  |  | — |  |  | 3 |
Segment earnings (loss) attributable to Humana | $ | 1,663 |  |  | $ | 578 |  |  |  |  |  |  | $ | (347) |  |  | $ | 1,894 |
| Insurance |  | CenterWell |  | Eliminations/ Corporate |  | Consolidated
Six Months Ended June 30, 2023 | (in millions)
External Revenues |  |  |  |  |  |
Premiums: |  |  |  |  |  |  |
Individual Medicare Advantage | $ | 39,558 |  |  | $ | — |  |  | $ | — |  |  | $ | 39,558 |
Group Medicare Advantage | 3,497 |  |  | — |  |  | — |  |  | 3,497 |
Medicare stand-alone PDP | 1,184 |  |  | — |  |  | — |  |  | 1,184 |
Total Medicare | 44,239 |  |  | — |  |  | — |  |  | 44,239 |
Commercial fully-insured | 1,968 |  |  | — |  |  | — |  |  | 1,968 |
Specialty benefits | 506 |  |  | — |  |  | — |  |  | 506 |
Medicare Supplement | 361 |  |  | — |  |  | — |  |  | 361 |
State-based contracts and other | 3,971 |  |  | — |  |  | — |  |  | 3,971 |
Total premiums | 51,045 |  |  | — |  |  | — |  |  | 51,045 |
Services revenue: |  |  |  |  |  |  |
Home solutions | — |  |  | 655 |  |  | — |  |  | 655 |
Primary care | — |  |  | 391 |  |  | — |  |  | 391 |
Commercial ASO | 135 |  |  | — |  |  | — |  |  | 135 |
Military services and other | 338 |  |  | — |  |  | — |  |  | 338 |
Pharmacy solutions | — |  |  | 458 |  |  | — |  |  | 458 |
Total services revenue | 473 |  |  | 1,504 |  |  | — |  |  | 1,977 |
Total external revenues | 51,518 |  |  | 1,504 |  |  | — |  |  | 53,022 |
Intersegment revenues |  |  |  |  |  |  |
Services | 29 |  |  | 2,277 |  |  | (2,306) |  |  | — |
Products | — |  |  | 5,254 |  |  | (5,254) |  |  | — |
Total intersegment revenues | 29 |  |  | 7,531 |  |  | (7,560) |  |  | — |
Investment income | 231 |  |  | — |  |  | 236 |  |  | 467 |
Total revenues | 51,778 |  |  | 9,035 |  |  | (7,324) |  |  | 53,489 |
Operating expenses: |  |  |  |  |  |  |
Benefits | 44,120 |  |  | — |  |  | (253) |  |  | 43,867 |
Operating costs | 4,963 |  |  | 8,319 |  |  | (7,192) |  |  | 6,090 |
Depreciation and amortization | 337 |  |  | 99 |  |  | (59) |  |  | 377 |
Total operating expenses | 49,420 |  |  | 8,418 |  |  | (7,504) |  |  | 50,334 |
Income from operations | 2,358 |  |  | 617 |  |  | 180 |  |  | 3,155 |
Interest expense | — |  |  | 1 |  |  | 232 |  |  | 233 |
Other expense, net | — |  |  | — |  |  | 46 |  |  | 46 |
Income (loss) before income taxes and equity in net losses | 2,358 |  |  | 616 |  |  | (98) |  |  | 2,876 |
Equity in net losses | (2) |  |  | (25) |  |  | — |  |  | (27) |
Segment earnings (loss) | $ | 2,356 |  |  | $ | 591 |  |  | $ | (98) |  |  | $ | 2,849 |
Net loss attributable to noncontrolling interests | 4 |  |  | — |  |  | — |  |  | 4 |
Segment earnings (loss) attributable to Humana | $ | 2,360 |  |  | $ | 591 |  |  | $ | (98) |  |  | $ | 2,853 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration